Pinto, Andrew D

Published purpose

The specific objectives of this funding opportunity are to: • Support an adaptive platform trial that is aimed at evaluating the effectiveness (including comparative clinical and cost-effectiveness), practical challenges, and outcomes of administering therapeutics for COVID-19 to non-hospitalized patients in Canadian healthcare settings using well-structured studies and well-defined outcome measures (e.g., the Core Outcomes Set (COS) for Trials in People With Coronavirus Disease 2019); • Generate evidence on treatment effectiveness diverse populations. These can include: communities marginalized by race; First Nations, Inuit, Métis and Urban Indigenous Peoples; communities historically excluded from research; those experiencing health inequities; persons with disabilities and individuals across diverse health status (e.g. vaccination status, high risk populations, individuals with comorbid conditions); those experiencing gendered impacts of the pandemic; and those in life stages that have been underrepresented in research. Across all populations, researchers are encouraged to consider a lifecycle approach (from preconception to older adulthood) where relevant and appropriate to the known safety profile of the treatments; and • Provide rapid evidence to inform clinical and health system management and public health response, and/or decision-making and planning within and across jurisdictions in Canada and internationally.